Digital and technological innovation strategies of the pharmaceutical industry

Summary

Context and objectives

Health is constantly evolving with new technologies, digital and data. The pharmaceutical industry must adapt its research & development department, discover new targets, accelerate the development to be more competitive, access the market and finally reach patients. The requirements are evolving and the pharmaceutical industry must understand them to enable future success.

Also, chemistry and biology have only allowed to identify a small part of the therapeutic possibilities. The arrival of data and AI has opened a whole new field of approaches.

Algorithms will contribute and are already contributing to tomorrow’s health through more efficient medical practices, better analysis of active ingredients and lower costs. It also allows a rapid synthesis of empirical knowledge and represents a support for personalized medicine and diagnosis.

The objectives of this study are:

Map and assess the main partnerships, collaborations, or innovations in the field of digital health
Get an overview of the key innovations depending of the life cycle management

What you will find in this study

The main partnerships, collaborations, exclusive relations, innovations in the field of digital health
An overview of the key innovations across the life cycle management

Methodology

This strategic report presents the main collaborations but is not exhaustive due to the huge amount of advances, new technologies, programs or partnerships in the field of digital health around the world. Also, the collaborations presented are recent or ongoing.

1. The methodology is based on desk research:
  - Website from institutions and private companies
  - Press releases
  - Financial reports
  - Specialized journals and newsletters
2. Books and publications
3. Identify the technological innovations throughout the life cycle management
4. Develop digital innovations in every step of the drug development process

Table of contents

Research, drug discovery
1.1. AI and data science
1.2. Digital twin
Drug development
2.1. AI and data science
2.2. Digital twin
Market access & treatment improvement
3.1. RWE
Post approval
4.1. CRM and Customer Data Management
4.2 Medical content & HCP engagement
4.3 Patient engagement
4.4 Apps, software & DTx
4.5 Programs, call for projects and incubators

Format

Language: English
Format: Secured PDF or PPT
Number of pages: around 170 slides

Authors

| Analyst: Laura Bailet, TechToMed

Terms & conditions

All contents of Service are the exclusive intellectual property of Techtomed SAS including trademarks, copyrights or any other form of intellectual property. Terms of a license provided by Company are governed by the Purchase and Licensing Agreement below.

Service licenses are designed to regulate readership and distribution rights.

The purchase of a single user license grants access to a specific report for one person only and must not be shared with other employees within the same company. Option A is available for industries and large companies (more than 50 employees). Option B concerns only start-up companies, SMEs (less than 50 employees) and public institutions.
For an extended license (multiple users, within the same department or company) or any other related specific requirement, please contact us at contact@techtomed.com

The report will be delivered to you online/by email in a secured PDF format within 24 hours of receipt of the completed and signed purchase order form.
Refund Policy : Please read all the available information about any report before placing your order. Due to the confidential nature of the information contained in our reports, cancellation of orders cannot be accepted after the report has been delivered.